University of Zurich (CH)
Access 250+ million papers and cite this researcher's work with AI assistance
H-index
154
Publications
2791
Citations
130644
i10-index
864
Want to find and read papers by this researcher? AnswerThis gives you instant access.
Sign Up Free| Title | Year | Citations |
|---|---|---|
Combined Nivolumab and Ipilimumab or Monotherapy i... | 2015 | 8183 |
Improved Survival with Vemurafenib in Melanoma wit... | 2011 | 7713 |
Overall Survival with Combined Nivolumab and Ipili... | 2017 | 5404 |
Five-Year Survival with Combined Nivolumab and Ipi... | 2019 | 3722 |
Genomic correlates of response to CTLA-4 blockade ... | 2015 | 2993 |
Vaccination of melanoma patients with peptide- or ... | 1998 | 2888 |
Improved Overall Survival in Melanoma with Combine... | 2014 | 2671 |
Improved Survival with MEK Inhibition in BRAF-Muta... | 2012 | 2146 |
Pembrolizumab versus investigator-choice chemother... | 2015 | 1568 |
Oncolytic Virotherapy Promotes Intratumoral T Cell... | 2017 | 1495 |
Reinhard Dummer is a researcher with 2791 publications and 130644 citations. They are affiliated with University of Zurich. Their research focuses on . With an h-index of 154, they are among the top researchers in their field.
Distribution of citations across publications
AnswerThis uses AI to help you search, understand, and cite research from Reinhard Dummer and 250M+ other papers.
Citations per publication by year